Compare ABAT & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABAT | DBVT |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.9M | 508.8M |
| IPO Year | N/A | N/A |
| Metric | ABAT | DBVT |
|---|---|---|
| Price | $4.01 | $18.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.46 |
| AVG Volume (30 Days) | ★ 6.0M | 452.4K |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,025,853.00 | ★ $5,502,000.00 |
| Revenue This Year | $145.40 | $1,768.71 |
| Revenue Next Year | N/A | $1,028.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 821.40 | N/A |
| 52 Week Low | $0.83 | $2.74 |
| 52 Week High | $11.49 | $21.50 |
| Indicator | ABAT | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 69.42 |
| Support Level | $3.86 | $17.86 |
| Resistance Level | $4.32 | $21.50 |
| Average True Range (ATR) | 0.34 | 1.22 |
| MACD | 0.09 | 0.63 |
| Stochastic Oscillator | 59.17 | 66.53 |
American Battery Technology Co is an integrated critical battery minerals company that develops technologies for both primary battery minerals manufacturing and lithium-ion battery recycling. It operates battery recycling facilities that process materials from electric vehicle batteries, stationary battery energy storage systems, and consumer electronics. Additionally, the company advances lithium production projects using proprietary technology to produce battery-grade lithium hydroxide. It generates revenue mainly from its recycling operations and is expanding capacity with strategic partnerships and government grants. The company's activities focus on creating a closed-loop battery materials supply chain to support sustainable manufacturing in the United States.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.